MedTrace Logo

Butyrate/Hexanoate in Metabolic Health

NCT04662411 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-11-29

No results posted yet for this study

Summary

In this study, we aim to identify a well consumable butyrate/hexanoate-enriched oil that increases circulating SCFA concentrations and improves postprandial substrate metabolism, which could be further used for a long-term study.

Conditions

  • Metabolic Disease

Interventions

DIETARY_SUPPLEMENT

Placebo

acute intake of 0 mg butyrate and hexanoate

DIETARY_SUPPLEMENT

butyrate and hexanoate amount 1

acute intake of 650 mg butyrate and hexanoate

DIETARY_SUPPLEMENT

butyrate and hexanoate amount 2

acute intake of 1325 mg butyrate and hexanoate

DIETARY_SUPPLEMENT

butyrate and hexanoate amount 3

acute intake of 2000 mg butyrate and hexanoate

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-13
Primary Completion
2021-07-26
Completion
2021-07-26

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04662411 on ClinicalTrials.gov